A safety-first self-assessment
Use this non-diagnostic screen to identify reasons to pause before considering ibogaine. It is designed for people researching ibogaine—not as a clearance decision, treatment recommendation, or substitute for medical care.
A concern on this page is a reason for qualified review, not a problem to work around.
Medical history, current medicines, ECG findings, and withdrawal state require professional assessment.
Evidence-based care, stabilization, and regulated research can be appropriate next steps.
Screen 01
Ibogaine should not be evaluated as a simple personal fit. The first question is whether health factors make consideration unsafe or inappropriate without specialist assessment.
Pause if there is cardiac disease, fainting, palpitations, an abnormal ECG, a known prolonged QT interval, or a family history that raises concern about rhythm disorders. QT prolongation can increase the risk of dangerous arrhythmias; the FDA’s discussion of QT-related abnormal heart rhythms illustrates why this category requires medical review.
Pause if there is significant hepatic or renal dysfunction, a history of serious liver disease, kidney disease, or unexplained abnormal laboratory findings. A self-assessment cannot determine how organ function may affect risk, monitoring needs, or whether another path is safer.
Pause if any current medication may prolong QT, affect heart rhythm, or act as an MAO inhibitor. Do not stop or adjust prescribed medicines to fit a plan. A qualified prescriber or pharmacist needs the complete medication list, including non-prescription products and supplements.
Pause if you are under legal adulthood, pregnant, breastfeeding, or could be pregnant. These circumstances require individualized medical discussion and are not suitable for self-clearance.
Screen 02
Pause if there is active psychosis, uncontrolled bipolar disorder, severe suicidality, severe confusion, or an inability to participate in a clear informed-consent conversation. These are not minor caveats. They are reasons to prioritize psychiatric stabilization and immediate support where needed.
Recent substance use, intoxication, acute withdrawal, or a rapidly changing withdrawal state can also undermine safety and decision-making capacity. The SAMHSA National Helpline guidance points people toward treatment referral and support options when substance use needs are current or urgent.
Stabilization, a mental-health evaluation, withdrawal care, or evidence-based addiction treatment is a safer priority than trying to force a yes-or-no answer about ibogaine.
A safer sequence
For people researching ibogaine, the practical value is in identifying the next safer question. This sequence is intentionally conservative.
Medical history, current medicines, psychiatric instability, pregnancy, age, or acute substance effects may all change the decision.
Do not interpret determination or prior experience as medical clearance. Do not alter medicines or attempt to manage withdrawal alone.
Seek appropriate medical, psychiatric, or addiction-care assessment based on the concern that surfaced.
Only regulated research or medically supervised programs with continuous cardiac monitoring belong in further consideration.
Screen 03
When this checklist identifies a concern, a safer alternative is not a failure of the process. It is the point of the process.
Evidence-based addiction treatment, psychiatric stabilization, and a discussion with a qualified healthcare professional may be more appropriate than further pursuit of ibogaine. People considering research may also want to review the clinical trial and care options overview before treating any pathway as settled.
Ibogaine is not approved by the U.S. Food and Drug Administration for treatment of substance use disorders. The agency’s drug development process overview describes why investigational substances require structured study and oversight rather than informal assumptions of safety or effectiveness.
Legal status and availability do not answer whether an option is medically appropriate. For a wider orientation to timing, experience, and practical questions, this guide to how long ibogaine effects may last can help frame questions without substituting for clinical review.
“The safest result from a self-assessment may be a pause: stabilize first, verify the facts, and consider only settings built for medical oversight.”
Practical questions
This page helps surface concerns. It cannot diagnose conditions, interpret an ECG, assess drug interactions, or establish informed consent.
No. It can identify reasons to pause, but it cannot replace clinical evaluation, medication review, ECG assessment, laboratory testing, or an informed-consent conversation. The general ibogaine background is also not a substitute for individualized risk assessment.
Treat it as a reason to pause and discuss the issue with a qualified healthcare professional. Depending on the concern, evidence-based addiction treatment, psychiatric stabilization, or regulated clinical research may be more appropriate.
No. Urgent medical, psychiatric, or withdrawal needs should be addressed first. For the broader evidence-and-safety framework behind this resource, return to the main ibogaine research guide rather than waiting for a self-assessment to resolve an urgent need.
Keep the threshold high
Ibogaine is investigational. Any further consideration should be limited to regulated research or medically supervised programs with continuous cardiac monitoring, after appropriate review of health history, medications, psychiatric stability, and current substance use.
Review the risk and monitoring guide